According to the Financial Times, Johnson & Johnson is considering acquiring Ollin Biosciences, a biotechnology company specializing in ophthalmic research and development, for up to $3.4 billion. Existing headlines and summaries describe it as a potential acquisition, indicating that the deal has not yet been signed or completed, and no specific payment structure has been provided.